Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer
| Autor: | Eiji Sakamoto, Masato Nagino, Seiji Ishiguro, Satoshi Kobayashi, Naoki Omiya, Akimasa Nakao, Hidemi Goto, Yuichiro Tojima, Masaya Inoue, Keisuke Uehara, Atsuyuki Maeda, Naoki Ishizuka |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Bevacizumab Oxaloacetates Colorectal cancer medicine.medical_treatment Phases of clinical research Adenocarcinoma Antibodies Monoclonal Humanized Deoxycytidine Disease-Free Survival Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans Radiology Nuclear Medicine and imaging Neoadjuvant therapy Capecitabine business.industry Rectal Neoplasms Standard treatment Antibodies Monoclonal General Medicine medicine.disease Total mesorectal excision Neoadjuvant Therapy Radiation therapy Treatment Outcome Research Design Fluorouracil business medicine.drug |
| Zdroj: | Japanese journal of clinical oncology. 41(8) |
| ISSN: | 1465-3621 |
| Popis: | In Western countries, the standard treatment for locally advanced rectal cancer is preoperative chemoradiotherapy followed by total mesorectal excision. On the other hand, in Japan, treatment results without radiotherapy are by no means inferior; therefore, extrapolation of results of preoperative treatment in Western countries to Japan is controversial. We consider that survival may be improved by preoperative treatment with new anticancer agents as they are expected not only to decrease the local recurrence rate but also to prevent distant metastases. We are conducting a multicentre Phase II study to evaluate the safety and efficacy of neoadjuvant chemotherapy using XELOX plus bevacizumab without radiotherapy in patients with locally advanced rectal cancer. The primary endpoint of the study is treatment compliance. Secondary endpoints are overall survival, disease-free survival, local recurrence-free survival, objective response rate, R0 resection rate and adverse events. Thirty patients are required for this study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|